FDA Grants Orphan Drug Designation to Kedrion's QIVIGY for Stiff Person Syndrome
核心洞察
The FDA has granted Orphan Drug Designation to Kedrion Biopharma (搜索)'s QIVIGY (搜索), an intravenous immune globulin, for the treatment of Stiff Person Syndrome (搜索).
Stiff Person Syndrome (搜索) is an ultra-rare immune-mediated disorder affecting roughly two per 100,000 people, with no FDA-approved treatment currently available.
QIVIGY (搜索) is already approved in the U.S. for adults with primary humoral immunodeficiency (搜索), and its safety and efficacy in SPS are under study in a clinical trial.
Kedrion Biopharma (搜索) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to immune globulin intravenous, human 10% solution (搜索), marketed as QIVIGY (搜索), for the treatment of Stiff Person Syndrome (搜索). The designation covers an ultra-rare, immune-mediated neurological disorder estimated to affect approximately two per 100,000 people, for which no products are currently approved in the United States.
Stiff Person Syndrome (搜索) is characterized by progressive muscle rigidity and painful, unpredictable muscle spasms. If left untreated, the condition can significantly affect a person's ability to perform routine tasks and movement. It is two to three times more common in women, and diagnosis is often delayed by years because of its rarity and its typical onset in midlife, between ages 30 and 50. Despite the availability of symptomatic treatments, Kedrion states that significant unmet patient needs remain.
"Orphan Drug Designation is an important regulatory and clinical milestone as we explore the potential of QIVIGY (搜索) to address the critical unmet need for people living with Stiff Person Syndrome (搜索)," said Nisha Jain, M.D., Vice President, Global Clinical Development and Strategy at Kedrion Biopharma (搜索). "This designation underscores Kedrion's scientific commitment to advancing plasma-derived therapies for rare and ultra-rare disorders, both through targeted drug development and by expanding the therapeutic reach of established therapies for underserved patient communities."
Regulatory Incentives and Development Status
The FDA grants Orphan Drug Designation to therapies intended to address rare diseases or conditions affecting fewer than 200,000 people in the United States at the time of designation. Under the Orphan Drug Act, the status carries incentives including tax credits, grants, and waiver of certain administrative fees for clinical trials, along with seven years of market exclusivity following drug approval.
QIVIGY (搜索) is currently approved in the U.S. for the treatment of adults with primary humoral immunodeficiency (搜索). Its safety and efficacy for Stiff Person Syndrome (搜索) are being assessed in a clinical trial registered as NCT 07552987. The product is not approved for SPS, and Kedrion notes that the safety and effectiveness of QIVIGY for this use have not been established.
Clinical Rationale and Investigator Perspective
"People living with Stiff Person Syndrome (搜索) continue to face significant diagnostic delays, progressive functional impairment, and limited strategies for symptom management," said Dr. Scott Newsome, Professor of Neurology and Director of the Johns Hopkins Stiff Person Syndrome Center of Excellence at Johns Hopkins University School of Medicine in Baltimore. "Evaluating QIVIGY (搜索) in structured clinical trials provides an opportunity to assess whether targeted intravenous immunoglobulin therapy can modify disease progression and meaningfully improve functional outcomes."
Patient advocacy representatives also commented on the development program. "People living with Stiff Person Syndrome (搜索) have long faced a severe lack of effective therapies for this disease," said Tara Zier, Founder and CEO of The Stiff Person Syndrome Research Foundation. "Seeing QIVIGY (搜索) being studied specifically for SPS brings excitement to a community that has spent years waiting for dedicated treatment options."
Product Profile and Safety Considerations
QIVIGY (搜索) (immune globulin intravenous, human-kthm) 10% solution is a liquid immune globulin formulation indicated for adults with primary humoral immunodeficiency (搜索). It carries a Boxed Warning regarding thrombosis, renal dysfunction and acute renal failure. For patients at risk of thrombosis, renal dysfunction or failure, the label directs administration at the minimum dose available and the minimum infusion rate practicable, with adequate hydration before administration and monitoring for signs and symptoms of thrombosis.
Other labeled warnings and precautions include severe hypersensitivity reactions such as anaphylaxis, hyperproteinemia, hyperviscosity, hyponatremia, aseptic meningitis syndrome, hemolysis, and transfusion-related acute lung injury. Because QIVIGY (搜索) is made from human plasma, it may carry a risk of transmitting infectious agents, including viruses and the variant Creutzfeldt-Jakob disease agent, and theoretically the Creutzfeldt-Jakob disease agent. The most common adverse reactions occurring in more than 5% of treated patients were headache, fatigue, infusion-related reaction, positive direct Coombs test, nausea, sinusitis, dizziness, and diarrhea.
Kedrion Biopharma (搜索) collects and fractionates blood plasma to produce and distribute plasma-derived therapies for rare, ultra-rare, and debilitating conditions, including coagulation and neurological disorders, immunodeficiencies, and Rh sensitization. The company employs approximately 5,400 people worldwide, operates plasma collection centers in the United States and the Czech Republic, and has a portfolio of 39 products distributed in more than 100 countries.